Pharmaceutical

Pernix Therapeutics (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL resolving patent litigation related to Zohydro ER. As quoted in the press release: “We are pleased to have settled the outstanding litigation and appeal with Actavis,” said John Sedor, Pernix’s Chairman and Chief Executive Officer. …

Pernix Therapeutics (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has entered into a settlement agreement with Actavis Laboratories FL resolving patent litigation related to Zohydro ER.
As quoted in the press release:

“We are pleased to have settled the outstanding litigation and appeal with Actavis,” said John Sedor, Pernix’s Chairman and Chief Executive Officer. “This agreement underscores the strength of our intellectual property around Zohydro® ER, and aids in reducing litigation costs.  We will continue to defend our existing patents, and intend to further expand our intellectual property portfolio around each of our core brands, including Zohydro® ER.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX20181.92+80.54
TSXV705.58+14.41
DOW31253.13-236.94
S&P 5003900.79-22.89
NASD11388.50-29.66
ASX7064.50-118.20

COMMODITIES

Commodities
Gold1844.55+2.37
Silver21.99+0.08
Copper4.290.00
Palladium2019.50+15.50
Platinum969.00+10.00
Oil111.65-0.56
Heating Oil3.68+0.01
Natural Gas8.10-0.21

DOWNLOAD FREE REPORTS

×